MADRIGAL PHARMACEUTICALS, INC. (MDGL): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617490d2_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Madrigal Pharmaceuticals 2026 Stock Plan (as amended from time to time, the “ Plan ”). The pur
How this was made
The 30-second read
Why it matters
Based on the excerpt alone, the incremental information is the existence/structure of the 2026 Stock Plan and related definitions (Awards, Change of Control, Cause/Good Reason). Without quantified grant amounts or named executive terms, the trading impact is likely limited.
Market read
Compensation-plan governance disclosure; potential minor read-through to future dilution/overhang, but no operational or financial catalyst is present in the provided text.
What to watch
Traders should check the full 8-K for the actual names/roles of departing directors/officers and any quantified award terms, severance, or Change-of-Control provisions that could affect dilution and governance risk.
Background
The filing is an SEC Form 8-K covering Item 5.02 (director/officer changes and compensatory arrangements) and Item 5.07 (matters submitted to a vote). The provided excerpt includes Exhibit 10.1 defining the Madrigal Pharmaceuticals 2026 Stock Plan.
Ticker impact
SEC 8-K Item 5.02 discloses director/officer departure and related compensatory arrangements tied to Madrigal’s 2026 Stock Plan framework.
Low near-term impact; any move would likely be limited to compensation/dilution expectations rather than fundamentals.
The excerpt is largely boilerplate plan definitions (options/RSUs/Awards, Change of Control, Cause/Good Reason) without specific new grant sizes, departures, or financial terms.
Market effects
Minimal; stock-plan/compensation disclosures are common across biotech and usually don’t change sector risk premia without quantified dilution or major executive changes.
None indicated.
None indicated.
Counterpoint
If the omitted portions of the 8-K include specific executive departures or unusually large equity awards, the market reaction could be more material than the plan boilerplate suggests.
Key entities
- companyMadrigal Pharmaceuticals, Inc.
Subject of the SEC 8-K; disclosed director/officer changes and compensatory arrangements tied to the 2026 Stock Plan.
